Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Non-Current Debt (2018 - 2025)

Abeona Therapeutics has reported Non-Current Debt over the past 7 years, most recently at $7.8 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $7.8 million for Q4 2025, down 40.07% from a year ago — trailing twelve months through Dec 2025 was $7.8 million (down 40.07% YoY), and the annual figure for FY2025 was $7.8 million, down 40.07%.
  • Non-Current Debt for Q4 2025 was $7.8 million at Abeona Therapeutics, down from $10.9 million in the prior quarter.
  • Over the last five years, Non-Current Debt for ABEO hit a ceiling of $18.1 million in Q1 2024 and a floor of $1.2 million in Q1 2021.
  • Median Non-Current Debt over the past 4 years was $8.4 million (2021), compared with a mean of $9.0 million.
  • Peak annual rise in Non-Current Debt hit 224.15% in 2022, while the deepest fall reached 51.39% in 2022.
  • Abeona Therapeutics' Non-Current Debt stood at $3.8 million in 2021, then rose by 8.75% to $4.2 million in 2022, then surged by 213.16% to $13.0 million in 2024, then crashed by 40.07% to $7.8 million in 2025.
  • The last three reported values for Non-Current Debt were $7.8 million (Q4 2025), $10.9 million (Q3 2025), and $14.0 million (Q2 2025) per Business Quant data.